Clinical trial
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve…
NCT00080899 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00080899 |
|---|---|
| Title | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer |
| Official title | A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | fenretinide, laboratory biomarker analysis |
| Enrollment | 23 |
| Start date | Jun 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Apr 8, 2004 |
| Last update posted | Mar 6, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: